Top 60 Distributors of Bioprocessing Supplies in China 2020 - Opportunities for Global Biopharma Suppliers to Find and Manage Local Distributors in China - ResearchAndMarkets.com

The "Top 60 Distributors of Bioprocessing Supplies in China: Opportunities for Global Biopharma Suppliers to Find and Manage Local Distributors in China" report has been added to ResearchAndMarkets.com's offering.

This report covers major distributors of bioprocessing supplies and equipment in the Peoples Republic of China (PRC). Distributor information includes company ownership, background, management, facility capacity and history.

The Directory is based on in-depth research, using public secondary and primary information research. This on-going project is regularly updated, and is intended to provide in-depth information and insights into the rapidly growing and changing Chinese biologics supplies industry.

Key Topics Covered

Chapter 1: Market Demands for High Quality Equipment & Single Use Systems

• Pipeline Growth in China, Market for mAb Therapeutics and Vaccines and Demand from Domestic Developers

Chapter 2: China's Local Bioprocessing Equipment Competition Landscape

• SWOT Analysis of China Domestic Vendors of Bioprocessing
• Opportunities
• Weaknesses
• Threats

Chapter 3: Distribution of Bioprocessing Products in China

• Why Western Vendors Should Use Distributors in China and How to Assess Chinese Distributors
• Distribution Models in China
• How to Manage Chinese Distributors

Chapter 4: Building a Relationship: Collaborations Between China Distributors and Western Vendors

• How to Start Looking for A Chinese Distributor
• What Types and How Many Distributors Should Be Hired
• Questions to be Asked and Answered Before Hiring a Distributor in China
• Priorities for a Western Manufacturer to Consider
• Typical Distributor Commissions and Other Commitments
• Process to Line up Distributor(s) in China
• Legal and Other Reviews
• Managing Distributors
• Failure Case Studies
  • Case 1
  • Case 2
• Successful Case Studies
  • Case 1
  • Case 2
  • Case 3
• How to Build a Successful Relationship with Distributors in China

Chapter 5: Regulatory Environment and Reforms Impacting China Biologics Manufacturing

• Drug Administration Law on Drug Manufacturing (2019)
• Impact of Regulatory Environment for Domestic and Foreign Investors

Chapter 6: Top 60 Distributor Company Profiles

• 3SBio
• AlphaMab
• Amoy-Top Biotech (subsidiary of Tonghua Dongbao)
• Anhui Anke Biotechnology
• Beigene
• BeigeneJunshi Pharma/Jiangsu Suzhou
• Benemae Pharmaceutical
• Biotech Pharma
• Boehringer-Ingelheim
• CP Guojian Pharmaceutical
• CSPC Pharma
• Celgene Pharma/Shanghai
• Changchun Hi-Tech #2 BCHT
• Changchun Hi-Tech GeneScience
• Changchun Institute
• Chengdu Institute
• Chia Tai Tianqing
• Four Rings
• GSK/Shenzhen
• Gan & Lee
• Generon
• Genor
• Henglius Pharma (a subsidiary of Fosun Pharma)
• Hengrui Pharma/Lianyungang
• Hengrui Pharma/Suzhou
• Hisun
• Huahai Pharma
• Hualan/Beijing
• Hualan/Xinxiang
• Innovent Bio
• JHL biotech
• Jiangsu Wanbang
• Junshi Pharma/Jiangsu, Suzhou
• Junshi Pharma/Ligang, Shanghai
• Kanghong Pharma
• Kelun Pharma
• Lanzhou Institute
• Lee's Pharma
• Livzon mAb
• Luye Pharma
• Mabtech holding Ltd
• North China
• Pfizer/Hangzhou
• Qilu Pharma
• SL Pharma/Beijing
• SL Pharma/Quebec
• Sanofi/Shenzhen
• ShangPharma (Chempartner)
• Shanghai Institute
• Shanghai Pharma
• Shanghai United Cell/Shanghai
• Simcere Pharma/Jiangsu, Changzhou
• Simcere Pharma/Yantai
• SinoCellTech
• Sinobioway/Tianjin
• Sinovac/Beijing
• Tasly
• Teruisipharm
• Tiantan Biologics
• Tonghua DongBao
• Tot Pharma
• Tri-Prime Gene
• Walvax/Kunming
• Walvax/Taizhou
• Walvax/Yuxi
• Wuhan Institute
• Wuxi Biologics
• Yantai Rongchang (MABPLEX,subsidiary of Yantai Rongchang )
• Zesun Pharma
• Zhuhai Essex

For more information about this report visit https://www.researchandmarkets.com/r/zgw5is

View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005243/en/